Details of the Drug

General Information of Drug (ID: DMMFCIH)

Drug Name
Clotrimazole
Synonyms
Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1], [2]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 344.8
Topological Polar Surface Area (xlogp) 5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
5% of drug is excreted from urine in the unchanged form [3]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.0713 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.003 mg/mL [3]
Chemical Identifiers
Formula
C22H17ClN2
IUPAC Name
1-[(2-chlorophenyl)-diphenylmethyl]imidazole
Canonical SMILES
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
InChI
InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
InChIKey
VNFPBHJOKIVQEB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2812
ChEBI ID
CHEBI:3764
CAS Number
23593-75-1
DrugBank ID
DB00257
TTD ID
D09GOS
VARIDT ID
DR00574
INTEDE ID
DR0362
ACDINA ID
D00959

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Modulator [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Fungal infection
ICD Disease Classification 1F29-1F2F
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 8.82E-01 -0.23 -0.21
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 1.34E-01 0.21 0.19
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.13E-01 4.03E-02 2.50E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.21E-02 8.17E-02 4.35E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Clotrimazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [26]
Methylergonovine DMBEX4O Moderate Decreased metabolism of Clotrimazole caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [27]
Repaglinide DM5SXUV Moderate Decreased metabolism of Clotrimazole caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [28]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Thioguanine. Acute myeloid leukaemia [2A60] [29]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Clotrimazole caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [30]
Terfenadine DM4KLPT Major Decreased metabolism of Clotrimazole caused by Terfenadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [31]
Donepezil DMIYG7Z Minor Decreased metabolism of Clotrimazole caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [32]
Ivabradine DM0L594 Major Decreased metabolism of Clotrimazole caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [30]
Bepridil DM0RKS4 Moderate Decreased metabolism of Clotrimazole caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [33]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Clotrimazole caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [34]
Nifedipine DMSVOZT Moderate Decreased metabolism of Clotrimazole caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [33]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [35]
Alprazolam DMC7XDN Moderate Decreased metabolism of Clotrimazole caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [36]
Cilostazol DMZMSCT Moderate Decreased metabolism of Clotrimazole caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [37]
Budesonide DMJIBAW Moderate Decreased metabolism of Clotrimazole caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [38]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Clotrimazole caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [39]
Cariprazine DMJYDVK Moderate Decreased metabolism of Clotrimazole caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [30]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Clotrimazole and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [40]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Clotrimazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Clotrimazole caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
HKI-272 DM6QOVN Major Decreased metabolism of Clotrimazole caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
LY2835219 DM93VBZ Moderate Decreased metabolism of Clotrimazole caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Clotrimazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Palbociclib DMD7L94 Moderate Decreased metabolism of Clotrimazole caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Clotrimazole caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Clotrimazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [46]
Toremifene DMQYUWG Moderate Decreased metabolism of Clotrimazole caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Bosutinib DMTI8YE Moderate Decreased metabolism of Clotrimazole caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Estradiol DMUNTE3 Moderate Decreased metabolism of Clotrimazole caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Atorvastatin DMF28YC Moderate Decreased metabolism of Clotrimazole caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [30]
Macitentan DMP79A1 Moderate Decreased metabolism of Clotrimazole caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [48]
PF-04449913 DMSB068 Moderate Decreased metabolism of Clotrimazole caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [49]
Indacaterol DMQJHR7 Minor Decreased metabolism of Clotrimazole caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [50]
Drospirenone DM1A9W3 Moderate Decreased metabolism of Clotrimazole caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [45]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Clotrimazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [45]
Ulipristal DMBNI20 Minor Decreased metabolism of Clotrimazole caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [30]
Etonogestrel DMKA8J4 Moderate Decreased metabolism of Clotrimazole caused by Etonogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [45]
Levobupivacaine DM783CH Moderate Decreased metabolism of Clotrimazole caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [30]
Ropivacaine DMSPJG2 Minor Decreased metabolism of Clotrimazole caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [51]
Alfentanil DMVO0UB Major Decreased metabolism of Clotrimazole caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [52]
Nimodipine DMQ0RKZ Moderate Decreased metabolism of Clotrimazole caused by Nimodipine mediated inhibition of CYP450 enzyme. Coronary vasospastic disease [BA85] [33]
Methadone DMTW6IU Moderate Decreased metabolism of Clotrimazole caused by Methadone mediated inhibition of CYP450 enzyme. Cough [MD12] [53]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Clotrimazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [54]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Clotrimazole caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [26]
Aprepitant DM053KT Moderate Decreased metabolism of Clotrimazole caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Vilazodone DM4LECQ Moderate Decreased metabolism of Clotrimazole caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [56]
Escitalopram DMFK9HG Minor Decreased metabolism of Clotrimazole caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [57]
OPC-34712 DMHG57U Major Decreased metabolism of Clotrimazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Venlafaxine DMR6QH0 Moderate Decreased metabolism of Clotrimazole caused by Venlafaxine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [26]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Clotrimazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [59]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Clotrimazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [60]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Clotrimazole and Ingrezza. Dystonic disorder [8A02] [61]
Diazepam DM08E9O Moderate Decreased metabolism of Clotrimazole caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Clotrimazole caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [63]
Stiripentol DMMSDOY Moderate Decreased metabolism of Clotrimazole caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Cannabidiol. Epileptic encephalopathy [8A62] [30]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Clotrimazole caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [33]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Clotrimazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [64]
Solifenacin DMG592Q Moderate Decreased metabolism of Clotrimazole caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [65]
Mirabegron DMS1GYT Minor Decreased metabolism of Clotrimazole caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [66]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Clotrimazole caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [67]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Clotrimazole caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [68]
Cisapride DMY7PED Moderate Decreased metabolism of Clotrimazole caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [69]
Ripretinib DM958QB Moderate Decreased metabolism of Clotrimazole caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [26]
Avapritinib DMK2GZX Moderate Decreased metabolism of Clotrimazole caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [30]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Clotrimazole caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [70]
Eplerenone DMF0NQR Major Decreased metabolism of Clotrimazole caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [71]
Boceprevir DMBSHMF Moderate Decreased metabolism of Clotrimazole caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [72]
Telaprevir DMMRV29 Moderate Decreased metabolism of Clotrimazole caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [72]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Clotrimazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [26]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Brentuximab vedotin. Hodgkin lymphoma [2B30] [73]
MK-1439 DM215WE Minor Decreased metabolism of Clotrimazole caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Clotrimazole caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [76]
Dolutegravir DMCZGRE Minor Decreased metabolism of Clotrimazole caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Etravirine DMGV8QU Moderate Decreased metabolism of Clotrimazole caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Lopinavir DMITQS0 Minor Decreased metabolism of Clotrimazole caused by Lopinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Clotrimazole caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Amprenavir DMLMXE0 Minor Decreased metabolism of Clotrimazole caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Atazanavir DMSYRBX Moderate Decreased metabolism of Clotrimazole caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Maraviroc DMTL94F Moderate Decreased metabolism of Clotrimazole caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Simvastatin DM30SGU Moderate Decreased metabolism of Clotrimazole caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [30]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Clotrimazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [82]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Clotrimazole and Teriflunomide. Hyper-lipoproteinaemia [5C80] [83]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Clotrimazole and BMS-201038. Hyper-lipoproteinaemia [5C80] [84]
Cerivastatin DMXCM7H Moderate Decreased metabolism of Clotrimazole caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [30]
Aliskiren DM1BV7W Moderate Decreased metabolism of Clotrimazole caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Nisoldipine DM7ISKJ Moderate Decreased metabolism of Clotrimazole caused by Nisoldipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Levamlodipine DM92S6N Moderate Decreased metabolism of Clotrimazole caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Isradipine DMA5XGH Moderate Decreased metabolism of Clotrimazole caused by Isradipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Verapamil DMA7PEW Moderate Decreased metabolism of Clotrimazole caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Clotrimazole caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Amlodipine DMBDAZV Moderate Decreased metabolism of Clotrimazole caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Felodipine DMOSW35 Moderate Decreased metabolism of Clotrimazole caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Retapamulin DM9JXB7 Minor Decreased metabolism of Clotrimazole caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [85]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Clotrimazole caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [26]
Eszopiclone DM8RZ9H Moderate Decreased metabolism of Clotrimazole caused by Eszopiclone mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [86]
Triazolam DMETYK5 Moderate Decreased metabolism of Clotrimazole caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Clotrimazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [87]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Clotrimazole caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [88]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Clotrimazole caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [89]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Methotrexate. Leukaemia [2A60-2B33] [30]
Pemigatinib DM819JF Moderate Decreased metabolism of Clotrimazole caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [30]
Crizotinib DM4F29C Moderate Decreased metabolism of Clotrimazole caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [90]
Brigatinib DM7W94S Moderate Decreased metabolism of Clotrimazole caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [26]
Ceritinib DMB920Z Moderate Decreased metabolism of Clotrimazole caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [91]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Clotrimazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [92]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Clotrimazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [93]
Osimertinib DMRJLAT Moderate Decreased metabolism of Clotrimazole caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [94]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Clotrimazole caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [95]
Selpercatinib DMZR15V Moderate Decreased metabolism of Clotrimazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [30]
Halofantrine DMOMK1V Major Decreased metabolism of Clotrimazole caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [96]
Quinine DMSWYF5 Moderate Decreased metabolism of Clotrimazole caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [26]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [97]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Idelalisib. Mature B-cell leukaemia [2A82] [98]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Clotrimazole caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [26]
IPI-145 DMWA24P Moderate Decreased metabolism of Clotrimazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [99]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Clotrimazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [100]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Clofarabine. Mature B-cell lymphoma [2A85] [101]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Clotrimazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [102]
Ponatinib DMYGJQO Moderate Decreased metabolism of Clotrimazole caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [103]
Selumetinib DMC7W6R Moderate Decreased metabolism of Clotrimazole caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [104]
Estrone DM5T6US Moderate Decreased metabolism of Clotrimazole caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [45]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Clotrimazole caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [60]
Conjugated estrogens DMLT0E1 Moderate Decreased metabolism of Clotrimazole caused by Conjugated estrogens mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [45]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Clotrimazole caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [60]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Clotrimazole caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [83]
Dihydroergotamine DM5IKUF Moderate Decreased metabolism of Clotrimazole caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [70]
Ubrogepant DM749I3 Moderate Decreased metabolism of Clotrimazole caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [105]
Flibanserin DM70DTN Moderate Decreased metabolism of Clotrimazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [106]
Panobinostat DM58WKG Moderate Decreased metabolism of Clotrimazole caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [107]
Nilotinib DM7HXWT Moderate Decreased metabolism of Clotrimazole caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [108]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Clotrimazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [30]
Imatinib DM7RJXL Moderate Decreased metabolism of Clotrimazole caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [109]
Dasatinib DMJV2EK Moderate Decreased metabolism of Clotrimazole caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [110]
Modafinil DMYILBE Minor Decreased metabolism of Clotrimazole caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [26]
Entrectinib DMMPTLH Moderate Decreased metabolism of Clotrimazole caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [111]
Sibutramine DMFJTDI Minor Decreased metabolism of Clotrimazole caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [112]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Clotrimazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [113]
S-297995 DM26IH8 Moderate Decreased metabolism of Clotrimazole caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [30]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Clotrimazole caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [114]
Olaparib DM8QB1D Moderate Decreased metabolism of Clotrimazole caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [115]
Butorphanol DM5KYPJ Major Decreased metabolism of Clotrimazole caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [116]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Clotrimazole caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [117]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Clotrimazole caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [118]
Oxycodone DMXLKHV Major Decreased metabolism of Clotrimazole caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [26]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Clotrimazole caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [119]
Lefamulin DME6G97 Moderate Decreased metabolism of Clotrimazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [120]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Clotrimazole caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [27]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Clotrimazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [121]
Progesterone DMUY35B Moderate Decreased metabolism of Clotrimazole caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [45]
Enzalutamide DMGL19D Moderate Decreased metabolism of Clotrimazole caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [122]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Clotrimazole caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [123]
Silodosin DMJSBT6 Moderate Decreased metabolism of Clotrimazole caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [124]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Clotrimazole caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [125]
Alfuzosin DMZVMKF Moderate Decreased metabolism of Clotrimazole caused by Alfuzosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [126]
Bosentan DMIOGBU Moderate Decreased metabolism of Clotrimazole caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [127]
Everolimus DM8X2EH Moderate Decreased metabolism of Clotrimazole caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [128]
Axitinib DMGVH6N Moderate Decreased metabolism of Clotrimazole caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [30]
Temsirolimus DMS104F Moderate Decreased metabolism of Clotrimazole caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [129]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Clotrimazole and Leflunomide. Rheumatoid arthritis [FA20] [83]
Quetiapine DM1N62C Moderate Decreased metabolism of Clotrimazole caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [130]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Clotrimazole caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [131]
Pimozide DMW83TP Moderate Decreased metabolism of Clotrimazole caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [132]
Fentanyl DM8WAHT Major Decreased metabolism of Clotrimazole caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [26]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Clotrimazole caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [133]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Clotrimazole caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [134]
LDE225 DMM9F25 Major Decreased metabolism of Clotrimazole caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [135]
Gefitinib DM15F0X Moderate Decreased metabolism of Clotrimazole caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [136]
Larotrectinib DM26CQR Moderate Decreased metabolism of Clotrimazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [30]
Armodafinil DMGB035 Minor Decreased metabolism of Clotrimazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
LEE011 DMMX75K Moderate Decreased metabolism of Clotrimazole caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Norethindrone DMTY169 Moderate Decreased metabolism of Clotrimazole caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [60]
Taxol DMUOT9V Moderate Decreased metabolism of Clotrimazole caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [137]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Clotrimazole and Naltrexone. Substance abuse [6C40] [138]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Clotrimazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [139]
Apixaban DM89JLN Moderate Decreased metabolism of Clotrimazole caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [30]
Brilinta DMBR01X Moderate Decreased metabolism of Clotrimazole caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [30]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Clotrimazole caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [140]
Sirolimus DMGW1ID Major Decreased metabolism of Clotrimazole caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [141]
Tacrolimus DMZ7XNQ Major Decreased metabolism of Clotrimazole caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [141]
Saxagliptin DMGXENV Moderate Decreased metabolism of Clotrimazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [30]
Elagolix DMB2C0E Moderate Decreased metabolism of Clotrimazole caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [142]
Fexofenadine DM17ONX Minor Decreased clearance of Clotrimazole due to the transporter inhibition by Fexofenadine. Vasomotor/allergic rhinitis [CA08] [143]
Astemizole DM2HN6Q Major Decreased metabolism of Clotrimazole caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [31]
Propafenone DMPIBJK Moderate Decreased metabolism of Clotrimazole caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [144]
Amiodarone DMUTEX3 Major Decreased metabolism of Clotrimazole caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [145]
⏷ Show the Full List of 188 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Cetyl alcohol E00061 2682 Coating agent; Emollient; Emulsifying agent; Stiffening agent
Phosphoric acid E00039 1004 Acidulant; Buffering agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium phosphate monobasic monohydrate E00428 516949 Buffering agent; Complexing agent
Stearyl alcohol E00172 8221 Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Water E00035 962 Solvent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clotrimazole eq 0.05% base cream eq 0.05% base Cream Topical
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2330).
2 Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
3 BDDCS applied to over 900 drugs
4 Clotrimazole Cream, DailyMed
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
7 Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9.
8 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
9 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
10 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
11 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
12 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
13 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
18 CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
19 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
20 Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
21 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
22 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
23 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
24 Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
25 Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589.
26 Cerner Multum, Inc. "Australian Product Information.".
27 Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904]
28 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
29 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
32 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
33 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
34 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
35 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
36 Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
37 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
38 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
39 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
40 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
41 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
42 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
43 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
44 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
45 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
46 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
47 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
48 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
49 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
51 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
52 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
53 Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM "The effect of fluconazole on the clinical pharmacokinetics of methadone." Clin Pharmacol Ther 63 (1998): 655-62. [PMID: 9663180]
54 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
55 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
56 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
57 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
58 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
59 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
60 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
61 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
62 Ahonen J, Olkkola KT, Neuvonen PJ "The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam." Fundam Clin Pharmacol 10 (1996): 314-8. [PMID: 8836707]
63 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
64 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
65 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
66 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
67 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
68 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
69 Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
70 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
71 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
72 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
73 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
74 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
75 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
76 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
77 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
78 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
79 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
80 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
81 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
82 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
83 Canadian Pharmacists Association.
84 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
85 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
86 Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
87 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
88 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
89 Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
90 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
92 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
93 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
95 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
96 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
97 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
98 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
99 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
100 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
101 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
102 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
103 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
104 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
105 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
106 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
107 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
108 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
109 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
110 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
111 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
112 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
113 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
114 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
115 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
116 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
117 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
118 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
119 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
120 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
121 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
122 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
123 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
124 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
125 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
126 Product Information. Uroxatral (alfuzosin). sanofi-aventis , Bridgewater, NJ.
127 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
128 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
129 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
130 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
131 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
132 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
133 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
134 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
135 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
136 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
137 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
138 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
139 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
140 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
141 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
142 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
143 Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
144 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.
145 Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]